Molecular drivers such as BRAF p.V600 mutations that are amenable to therapeutic intervention (with a combination of BRAF and MEK inhibitors) are uncommon in mucosal melanomas (<10% of cases) as compared to cutaneous melanoma, where approximately 40% are BRAF mutant; of these 74% are the V600E genotype and 22% are V600K [5–9]. Here, BRAF is linked to cutaneous melanoma.